anamorelin hydrochloride
AssetAlso called anamorelin, anamorelin HCl, RC-1291 HCl, RC-1291
Activates ghrelin receptors to stimulate appetite and growth hormone release.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- GHSR
- 19
- Indications
- 10
- Trials
- 3
- Developers
2 trials are still running. Trial NCT03035409 updated in its registry on Nov 10, 2026. clinicaltrials.gov
Indications
19Non-small cell lung cancer
Phase 3, Completed, NCT03743064, clinicaltrials.gov, Oct 23, 2026
Cachexia
Phase 3, Completed, NCT01395914, clinicaltrials.gov, Nov 5, 2026
Cachexia cancer
Phase 3, Completed, NCT03743064, clinicaltrials.gov, Oct 23, 2026
16 more
In the full profile
- Target and mechanism2
- Owner and partners3
- Trials10
- Evidence for its targets2
- Competitors12
- Signals7
Every asset’s record: target, stage, trials and the evidence behind it.